It was one year ago this month that Ashley McEvoy announced her surprising resignation as worldwide chair of J&J MedTech. She ...

Johnson & Johnson MedTech has concluded subject enrolment for the pilot phase of the OMNY-AF study of the investigational ...

Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Oct. 10, 2024 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, announced the first phase of the VOLT™ Variable Angle Optimized Locking ...

Johnson & Johnson's stock shows bearish pressure ahead of Q3 earnings, trading below key moving averages despite MedTech growth. The V-Wave acquisition strengthens J&J’s portfolio, but setbacks ...

The innovative medicine and medtech segments showed solid sales growth. Johnson & Johnson reported a strong increase in sales, but earnings fell due to one-time charges. In the wake of last year's ...

Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

WEST CHESTER, Penn., Oct. 10, 2024 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, announced the first phase of the VOLTTM Variable Angle ...